CQC Unveils New Strategy
The Care Quality Commission (CQC) has launched a new strategy to make a positive impact on patient care while regulating "in a targeted way".
The strategy is based on extensive consultation, with the public, health and social care providers, partner organisations, and charities. It is designed to respond to how the world of health and social care has changed since the CQC was established over a decade ago.
The strategy has four themes:
- People and communities
- Safety through learning
- Smarter regulation
- Accelerating improvement
Booster COVID-19 Vaccine Clinical Trial Launches
Health and Social Care Secretary, Matt Hancock, announced a new clinical trial to provide data on the impact of a third 'booster' dose of the COVID-19 vaccination.
The study will take place at 16 sites across England, as well as sites in Wales and Scotland, and will include 2,886 participants. It is led by University Hospital Southampton NHS Foundation Trust and is backed by £19.3m of government funding through the Vaccines Taskforce.
Booster vaccinations are due to begin in early June and initial findings are expected in September. Those findings will help the Joint Committee on Vaccination and Immunisation (JCVI) with plans for a booster programme in autumn this year.
Roche UK Launches Renewable Energy Initiative with E.ON
Starting from October, a new renewable energy initiative between Roche UK and E.ON the energy supplier, will allow Roche's supply chain partners to access up to 100% renewable energy guarantees of origin (REGO) wind backed electricity at a competitive rate.
At present, Roche's UK businesses use 100% renewable wind-back energy, and the company has a ten-year ambition to reduce its overall environmental footprint by 50%. This new initiative allows supply chain partners to purchase 100% renewable energy, in order to support suppliers in reducing their overall environmental impact.
GSK and Sanofi Launch COVID-19 Vaccine Study
GSK and Sanofi have begun enrolment for a Phase III clinical study of their COVID-19 vaccine candidate.
The study will include more than 35,000 volunteers and tests the adjuvanted recombinant-protein vaccine's ability to prevent symptomatic COVID-19. Positive results in the Phase II trial showed high rates of neutralising antibody responses, and the vaccine has now been advanced to Phase III.